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Ceramide is an important lipid signaling molecule that plays
critical roles in regulating cell behavior. Ceramide synthesis is
surprisingly complex and is orchestrated by six mammalian
ceramide synthases, each of which produces ceramides with
restricted acyl chain lengths. We have generated a CerS2 null
mouse and characterized the changes in the long chain base and
sphingolipid composition of livers from these mice. Ceramide
and downstream sphingolipids were devoid of very long (C22–
C24) acyl chains, consistent with the substrate specificity of
CerS2 toward acyl-CoAs. Unexpectedly, C16-ceramide levels
were elevated, and as a result, total ceramide levels were unal-
tered; however, C16-ceramide synthesis in vitro was not
increased. Levels of sphinganine were also significantly ele-
vated, by up to 50-fold, reminiscent of the effect of the ceramide
synthase inhibitor, fumonisin B1. With the exceptions of glu-
cosylceramide synthase and neutral sphingomyelinase 2, none
of the other enzymes tested in either the sphingolipid biosyn-
thetic or degradative pathways were significantly changed.
Total glycerophospholipid and cholesterol levels were unal-
tered, although therewas amarked elevation inC18:1 andC18:2
fatty acids in phosphatidylethanolamine, concomitant with a
reduction in C18:0 and C20:4 fatty acids. Finally, differences
were observed in the biophysical properties of lipid extracts
isolated from liver microsomes, with membranes from CerS2
null mice displaying higher membrane fluidity and showing
morphological changes. Together, these results demonstrate
novel modes of cross-talk and regulation between the various
branches of lipid metabolic pathways upon inhibition of very
long acyl chain ceramide synthesis.
Biological membranes contain thousands of different lipid
species that can be broadly classified according to their back-
bone structure (1). Of these, sphingolipids (SL)2 have become
particularly prominent due to the discovery of their unexpected
structural complexity and their intricate modes of cellular traf-
ficking andmetabolism (2–4). Ceramides are perhaps themost
well studied class of SLs, because of their essential roles in dif-
ferentiation and in apoptosis (5–7).
Ceramides can differ in both their long chain sphingoid base
(8) and fatty acid composition (9). Over the past few years, a
complex mode of regulation of ceramide synthesis has been
described, with each of the six mammalian ceramide synthase
(CerS) (formerly known as Lass (longevity assurance)) genes
generating ceramides with specific acyl chain lengths (10).
Thus, CerS1 uses mostly C18-CoA (11); CerS4 uses C18- and
C20-CoAs (12); CerS5 and CerS6 usemostly C16-CoA (12, 13);
and CerS3 uses very long chain acyl-CoAs (C26 and higher)
(14). CerS2 can utilize a wider range of fatty acyl-CoAs but uses
mainly C22 to C24. In addition, CerS2 displays complex modes
of regulation and has genomic features characteristic of a
“housekeeping” gene, although no other CerS genes display
these characteristics (15).
We have now generated a CerS2 null mouse and have sys-
tematically dissected the changes in SL levels in the livers of
these mice during the first 4 months of their development.
These analyses extend the recent study by Imgrund et al. (16),
inasmuch as we provide data on the changes in SL levels during
mouse development. Our study alsomeasures changes in levels
of sphingoid long chain bases and is consistent with the idea
that the dramatic pathological changes that occur in the liver of
thesemice (17) are likely due to a combination of changes in the
acyl chain composition of SLs as well as changes in long chain
base (predominantly sphinganine) levels. Finally, we have ana-
lyzed the activity of a number of enzymes of SL metabolism,
including neutral sphingomyelinase 2 (N-SMase 2), whose lev-
els are significantly elevated, andwe have also analyzed changes
in the biophysical properties of microsomal lipids. Significant
and unexpected changes are observed that together suggest
complex modes of interaction between components of the SL
metabolic pathway.
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EXPERIMENTAL PROCEDURES
Materials—D-Erythro-[4,5-3H]sphinganine (80 Ci/mmol)
was synthesized as described previously (18). Fatty acyl-CoAs,
ceramides, C6-NBD-sphingomyelin (SM), C6-NBD-glucosyl-
ceramide (GlcCer), C12-NBD-ceramide, C6-NBD-ceramide,
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine
rhodamine B sulfonyl) (Rho), and the internal standards for
liquid chromatography electrospray ionization-tandem mass
spectrometry (ESI-MS/MS) were purchased from Avanti Polar
Lipids (Alabaster, AL). Sphinganine was from Matreya (Pleas-
ant Gap, PA). Silica gel 60 TLC plates were from Merck. A
protease inhibitor mixture was from Sigma. 1,6-Diphenyl-
1,3,5-hexatriene (DPH) and trans-parinaric acid (t-PnA) were
fromMolecular Probes (Leiden, The Netherlands). Dulbecco’s
modified Eagle’s medium was from Invitrogen or Sigma. All
solvents were of analytical grade and were purchased from Bio-
lab (Jerusalem, Israel).
Mice—All mice were maintained under pathogen-free con-
ditions and handled according to protocols approved by the
Weizmann Institute Animal Care Committee as per interna-
tional guidelines.
PCRMethods andPrimers forGenotypingMice—Genotyping
was performed by PCR using primers that detect the wild type
CerS2 (CerS2) and the gene-trapped CerS2 (CerS2GT) alleles
in one reaction, using a mixture of three primers as follows:
forward (264), 5-GTAGTGCTCTCCATCATG-3; forward
(564), 5-CAGACACAGATAAGTTGC-3; reverse (432),
5-CATACAAGGTCTGGAGC-3. PCR cycleswere 95 °C for 3
min (95 °C for 30 s, 57 °C for 30 s, and 72 °C for 1.5 min) for 35
cycles and 72 °C for 3 min. TaqDNA polymerase master mix
(Amplicon) was used. A 1537-bp band was detected for the
CerS2 allele and a 1258-bp band for the CerS2GT allele (see
supplemental “Experimental Procedures”). For full-length
reverse transcription-PCR analysis of CerS2, the following
primers were used: forward (314), 5-GATGCTCCAGACCT-
TGTATGAC-3; reverse (590), 5-TTGTTATTGAGGAT-
GGGGTG-3. PCR cycles were as above. Further details are
given in the supplemental material.
Lipid Biochemistry—CerS activity was assayed using [3H]sph-
inganine and acyl-CoAs of different chain lengths (15, 19) using
150g of protein. Neutral sphingomyelinase (SMase) activity was
assayed using C6-NBD-SM (20), and other enzymes were mea-
sured according to the following protocols: SM synthase using
C6-NBD-ceramide (20); acid, alkaline, and neutral ceramidases
using C12-NBD-ceramide (21); GlcCer synthase using C6-NBD-
ceramide (22); acid SMase using C6-NBD-SM (20); glucosylcer-
amidase using C6-NBD-ceramide (23).
CerS mRNA Expression—cDNA was synthesized and deter-
mined by quantitative PCR using TaqManTM analysis and a
7300 sequence detection system (15). The following primers
were used: CerS2 sense, 5-GGCGCTAGAAGTGGGAAAC-
3; antisense, 5-TCGAATGACGAGAAAGAGCA-3. For
CerS4, -5, and -6, and for TATA-binding protein, which was
used as an endogenous control, see Ref. 15.
Lipid Analysis—SL analyses by ESI-MS/MS were conducted
using a PE-SciexAPI 3000 triple quadrupolemass spectrometer
and anABI 4000 quadrupole-linear ion trapmass spectrometer
(12, 15, 24, 25), as were acyl-CoA levels (26). Glycerophospho-
lipids and cholesterol were measured by nano-ESI-MS/MS (27,
28). All data are expressed per dry weight. Total cholesterol was
measured by ferric chloride (29).
Neutral SMase Expression—N-SMase 1 and -2 mRNA
expression was measured by reverse transcription-PCR using
the following primers: N-SMase 2 forward, 5-GAGCAGCTA-
CACGGCTACTTC-3, and N-Smase 2 reverse, 5-GAGAC-
CGTTTGTGTCCAGCAG-3 to yield a 546-bpDNA fragment;
N-SMase 1 forward, 5-CAATCTCAACTGCTG-3, and
N-Smase 1 reverse, 5-GAGTCACGTAGGCATTGAG-3 to
yield a 371-bp DNA fragment. Hypoxanthine-guanine phos-
phoribosyltransferase 1 primers were as follows: forward,
5-TCCAACACTTCGAGAGGTCC-3, and reverse, 5-GGG-
GGCTATAAGTTCTTTGC-3.
Membrane Biophysics and Morphology—The biophysical
properties of membranes were examined after preparing lipid
vesicles (0.3 mM phospholipid in phosphate-buffered saline)
(30) frommicrosomal lipid extracts (31). During vesicle prepa-
ration, all the samples were re-equilibrated by freeze-thaw
cycles. For studies with t-PnA and DPH, the samples were
slowly brought to room temperature, and the probe was added
from an ethanol stock solution. The samples were again re-
equilibrated by freeze-thaw cycles and subsequently kept over-
night at 4 °C. Before measurements, the samples were slowly
brought to room temperature and maintained at this tempera-
ture at least for 1 h. Fluorescence anisotropy was measured (10
measurements for each analysis) in a FluoroLog-3 fluorimeter
(Horiba Jobin-Yvon, Edison, NJ) using t-PnA, Rho, or DPH (at
final probe concentrations of 0.7, 0.5, and 0.8M, respectively).
All measurements were performed in 0.5  0.5 cm quartz
cuvettes undermagnetic stirring. The excitation (ex)/emission
(em) wavelengths were 320/405 nm for t-PnA, 358/430 nm for
DPH, and 570/593 nm for Rho.
Membranemorphology was studied by fluorescencemicros-
copy using a Leica TCS SP5 (Leica Microsystems CMS GmbH,
Mannheim, Germany) inverted microscope (DMI6000) with a
63 water (1.2 numerical aperture) apochromatic objective.
Giant unilamellar vesicles were prepared by electroformation
(32) usingmicrosomal lipid extracts. Rhowas used at a probe to
lipid ratio of 1:500.
Protein Phosphatase 2A—Protein phosphatase 2A activity
was measured as described previously (33, 34).
Statistics—All data are shown as means  S.E. (unless indi-
cated). p values were calculated using two independent samples
of a one-tailed Student’s t test. A p value0.05 was considered
statistically significant.
RESULTS
A CerS2 null mouse was generated from embryonic stem
cells harboring a gene trap (GT) retroviral vector insertion in
the first intron of the CerS2 gene (Fig. 1A) (35). Intercrossing
CerS2GT/ mice (F1 of 129S4/SvJae  C57BL/6) resulted in
generation of F2 CerS2GT/GT (CerS2 null) mice (Fig. 1B), which
were born with normal Mendelian inheritance ratios but
weighed 20–30% less than wild type (WT) mice (Fig. 1C).
CerS2 null mice do not normally survive beyond16 months,
although occasionally mice survived as long as 20 months (17).
LipidMetabolism in a Ceramide Synthase 2 Null Mouse
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CerS2 Null Mice Display Changes in the Acyl Chain Compo-
sition of SLs—Analysis of ceramide synthesis in homogenates
from mouse liver (which contains high levels of CerS2 mRNA
(15)) demonstrated that synthesis of ceramides containing very
long acyl chains (C22–C24)was reduced by95% inCerS2 null
mice (Fig. 2), as predicted from the acyl chain specificity of
CerS2 (15). The small residual amounts of C22–C24-ceramide
synthesis may be due to the sensitivity of the assay or due to the
reverse activity of ceramidase; alternatively, other CerS (i.e.
CerS3 and CerS4) may be able to synthesize small amounts of
C22–C24-ceramides, although the data largely support the
functional nonredundancy of CerS2 with respect to acyl chain
lengths.
ESI-MS/MS analysis of the changes in SL levels versus devel-
opment of the CerS2 null mouse corroborated that CerS2 null
mouse liver contained only trace amounts of very long acyl
chain ceramides compared with WT (Fig. 3 and Table 1) and
significantly reduced levels of long acyl chain SM and HexCer
(supplemental Tables 1 and 2) at all stages of mouse develop-
ment. Thus, levels of C22-, C24:0-, andC24:1-SLswere reduced
by 10–100-fold in the CerS2 null mouse, but no significant
reduction was seen in C20-SLs. Levels of C26:1- and C26:0-SLs
were relatively low in the WT, and only a small reduction was
observed in their levels in the CerS2 null mouse.
Unexpectedly, levels of C16-ceramide and C16-SLs were
increased (Fig. 3, Table 1, and supplemental Tables 1 and 2),
and this increase compensated for the loss of C22–C24-cera-
mides such that total ceramide levels (i.e. the sum of individual
ceramide species containing all acyl chains) were essentially
unaltered (Table 2). Thus, CerS2 null mice are not depleted in
total ceramide levels but rather show a change in their acyl
chain composition.
C16-ceramide was the only ceramide species whose level
increased (Table 1), and the increasewas detectable at birth; the
extent of the increase in C16-ceramide did not alter signifi-
cantly during subsequent development (up to 120 days of age)
(Table 1). Likewise, C16-SM was elevated from birth to 120
days of age (supplemental Table 2), as was C16-HexCer,
although HexCer levels in liver were significantly lower than
those of SM, and therefore the changes in HexCer levels were
more variable (supplemental Table 2).
CerS2 Null Mice Display Changes in Levels of Long Chain
Bases—In addition to the unexpected elevation of C16-SLs, a
massive elevation of sphinganine was observed (Fig. 3 and
FIGURE 1. Generation and characterization of CerS2 null mice. A, CerS2 null mice were created by crossing CerS2GT/ mice generated from a gene trap
embryonic stemcell line (stock number 013236-UCD,MutantMouseRegional ResourceCenter). Theupper panel shows theRosafary gene trap retroviral vector
used to generate CerS2 gene trap embryonic stem cells (35). A splice acceptor (SA) is located upstream to a -geo gene (neo resistance lacZ genes), which
is followed by a polyadenylation sequence (pA). A selectable marker for hygromycin (hyg) resistance is expressed under the phosphoglycerate kinase (PGK)
promoter, followed by a splice donor (SD) sequence, which is within two frt sites that are recognized by Flp recombinase. Elements of this vector are marked
as gray boxes. The vectorwas insertedbetween exons 1 and 2of the CerS2 gene (dashed lines). Exons aremarked as black boxes, and translational start and stop
sites are shown as arrows. A spliced transcript of theWT locus is also shown. The lower panel shows the integration of the retroviral vector into the CerS2 gene,
leading to generation of two transcripts. Transcript 1 is generated by splicing exon 1 of CerS2 (5-untranslated region) into the Rosafary splice acceptor,
resulting in expression of lacZ under the CerS2 promoter. The second transcript is driven by the PGK promoter of the hygromycin gene, which is spliced into
the second exon of CerS2. B, CerS2 null mice do not express full-length transcript 2, demonstrated using primers that amplify the full-length CerS2 transcript.
C,weight of CerS2 null mice. *, p 0.01; n 5.
FIGURE 2. Ceramide synthesis in CerS2 null mouse liver. The synthesis of
C22- or C24-ceramides is highly reduced in the CerS2 null mouse; the inset
shows C16-ceramide synthesis, which is unchanged. *, p 0.05; n 3.
LipidMetabolism in a Ceramide Synthase 2 Null Mouse
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Table 3), reaching levels as high as 95 pmol/mg of tissue, an
50-fold elevation compared withWT. Interestingly, sphinga-
nine levels were high at birth in both WT and CerS2 null mice
(Table 3) and subsequently decreased to levels of 1–2
pmol/mg of tissue inWTmice; in contrast, in CerS2 null mice,
sphinganine levels started to increase after21 days of age and
reached levels similar to those at birth after about 1 month.
Sphinganine was the only long chain base whose levels
increased significantly, as levels of the important signalingmol-
ecules, sphingosine 1-phosphate and sphinganine 1-phosphate,
were unchanged, and only a small change in sphingosine levels
was observed (Table 3). However, no significant changes in lev-
els of the second substrate of the CerS reaction, acyl-CoA, were
detected (Fig. 4).
Changes in Levels of Other Enzymes of SLMetabolismCannot
Explain the Changes in the SL Profile—Todetermine themech-
anism responsible for the changes in SL acyl chain length and in
sphinganine levels, we analyzed the mRNA expression levels
and the activity of a number of enzymes in the SL metabolic
pathway. mRNA levels of CerS5, which synthesizes C16-cera-
mide (12, 13), were elevated2.5-fold, whereasmRNA levels of
CerS6 (13), which can also synthesize C16-ceramide, were
unaltered (Fig. 5). However, the increased mRNA levels do not
result in changes in CerS5 (or CerS6, see also Ref. 36) enzyme
activity, because C16-ceramide synthesis in vitrowas unaltered
(Fig. 2, inset). CerS1 and CerS3 mRNAwas undetectable (data
not shown).
FIGURE 3. Ceramide and long chain base levels in CerS2 null mouse liver.
Ceramide and sphinganine levels in CerS2 null mice versus age of the mice,
measured by ESI-MS/MS. C24:1-ceramide is shown as an example of a very
long acyl chain ceramide; data for the other very long acyl chain ceramides
are in Table 1. For day 0, n 4; for other time points, n 2. *, p 0.05; **, p
0.01.
TABLE 1
Ceramide composition of CerS2WT and null mouse liver
Measurements were made by ESI-MS/MS. For day 0, n 4, and for all other time points, n 2. Statistical analysis was performed as indicated, a versus b, h versus i, p
0.01; c versus d, e versus f, f versus g, j versus k, l versusm, p 0.05.
LipidMetabolism in a Ceramide Synthase 2 Null Mouse
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Systematic analysis of enzymes that either utilize ceramide as
a substrate or produce it, including SM synthase, acid, alkaline,
and neutral ceramidases and acid SMase, revealed no change in
activity in either 14- or 30-day-old mice (Fig. 6). The only bio-
synthetic enzyme whose activity was altered was GlcCer syn-
thase, which showed an2-fold elevation in activity (Fig. 6). In
addition, levels of N-SMase 2 mRNA, but not N-SMase 1 (Fig.
7), were elevated in CerS2 null mice, resulting in increased
N-SMase activity in the liver starting at 14 days of age (Fig. 7).
Changes in Glycerophospholipid and Cholesterol Levels—No
changes were observed in glycerophospholipid levels between
WT and CerS2 null mice. Thus,
total phosphatidylcholine com-
prised 50% of the total glycero-
phospholipids in both WT and
CerS2 null mouse liver, and phos-
phatidylethanolamine comprised
30% (Fig. 8A). However, there
were significant differences in the
distribution of acyl chains in phos-
phatidylethanolamine, with a signif-
icant reduction in 18:0 fatty acids
and in the polyunsaturated fatty
acid, C20:4, and a significant elevation in unsaturated fatty
acids (C18:1 and C18:2) (Fig. 8B). Cholesterol levels were unal-
tered between the WT and CerS2 mice (Fig. 9).
Functional Consequences of Altered SL Levels—To examine
the functional consequences of altered SL levels, two properties
were examined that have been reported to depend on the acyl
chain composition of SLs. First, small but significant differ-
ences were observed in the biophysical properties of lipid
extracts isolated from liver microsomes, with membranes from
CerS2 null mice displaying highermembrane fluidity (Fig. 10A)
as shown by the lower anisotropy of t-PnA and DPH in CerS2
null membranes. This was confirmed by the increase in Rho
anisotropy in CerS2 null membranes. In fluid membranes, Rho
anisotropy increases because it distributes homogeneously in
the membrane, and energy homotransfer is minimized. In
membranes containing ordered regions, Rho is confined to the
more fluid areas leading to an increase in energy homotransfer
and a consequent decrease in anisotropy (30). Nevertheless, the
extent of the change was not as large as might have been pre-
dicted based on the large change in the sphingolipid profile
FIGURE 4. Levels of acyl-CoAs. Levels of fatty acyl-CoAs were analyzed by ESI-MS/MS in 30-day-old WT and
CerS2 null mouse livers and are shown as a ratio. n  2. There were no statistically significant differences
between WT and the CerS2 null mouse.
FIGURE 5. Levels of CerS mRNA expression. mRNA was isolated from
1-month-old WT and CerS2 null mice. n 5; *, p 0.005.
TABLE 2
Total SL levels in WT and CerS2 null mouse liver
The data are the sum of the individual SL species shown in Table 1 and supplemental Tables 1 and 2.With the exception of ceramide on day 7, SM on day 120, and HexCer
on days 7 and 14 (p 0.05), total ceramide, SM, and HexCer levels between WT and CerS2 null mice were statistically indistinguishable.
Age Ceramide SM HexCerWT CerS2 null WT CerS2 null WT CerS2 null
days pmol/mg tissue
0 282 49 203 47 1153 238 1402 510 54.0 5.6 52.8 9.4
7 220 30 114 7 979 215 707 29 75.1 3.5 48.0 6.0
14 104 0 121 18 707 109 827 47 86.0 11.1 50.1 1.3
21 152 12 117 41 920 16 1253 304 99.3 20.2 57.2 15.7
30 171 70 149 4 859 302 887 42 40.1 23.3 29.6 1.6
60 175 99 264 199 780 280 1093 423 37.5 19.5 48.9 25.9
120 193 23 247 15 559 62 1180 69 19.1 6.8 49.1 15.7
TABLE 3
Long chain base composition of WT and CerS2 null mouse liver
Measurementsweremade by ESI-MS/MS. For day 0, n 4, and for all other time points, n 2. Differences between sphinganine levels in theWT versus theCerS2 nullmice
were statistically significant (p 0.05). The only other statistically significant differences in long chain base levels inWT versusCerS2 null mice were between sphingosine
levels on days 30 and 120 (p 0.05) and in sphinganine 1-phosphate levels on days 120 (p 0.05). a versus b, b versus c, and d versus e, p 0.05; e versus f, p 0.01.
Age Sphingosine Sphinganine Sphingosine 1-phosphate Sphinganine 1-phosphateWT CerS2 null WT CerS2 null WT CerS2 null WT CerS2 null
days pmol/mg tissue
0 31.8 8.0 43.1 15.0 7.0 1.5 62.0 22.1 0.2 0.0 0.3 0.1 0.9 0.03 1.2 0.6
7 13.1 1.9 10.5 1.0 4.7 1.4 19.3 0.7 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.1
14 9.7 0.7 9.6 0.6a 2.9 0.6 14.0 3.3d 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0
21 11.0 1.7 16.3 0.9b 3.1 0.1 26.8 1.1e 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0
30 12.0 0.9 20.7 0.3c 1.8 0.5 54.3 0.6f 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0
60 17.2 5.7 38.7 21.3 1.8 0.3 94.4 61.2 0.1 0.1 0.0 0.2
120 15.3 2.2 32.8 4.6 1.3 0.4 73.3 22.1 0.1 0.0 0.1 0.0 0.1 0.0 0.4 0.1
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(Tables 1 and supplemental Tables 1 and 2), suggesting that
compensatory changes occur in CerS2 null mice so as to main-
tain membrane fluidity. Despite the small differences observed
in membrane fluidity, CerS2 null membranes displayed strong
morphological alterations, including membrane fusion, bud-
ding, tubule formation, and vesicle adhesion, compared with
WT membranes (Fig. 10B).
Second, we examined the activity of protein phosphatase 2A,
whose activity is known to be modified by the acyl chain com-
position of ceramides (37). Protein phosphatase 2A activity was
unchanged (Fig. 11), which is in agreement with studies sug-
gesting a role of C18-ceramide, but not C16-ceramide (whose
levels are elevated in the CerS2 null
mouse liver, Fig. 3) (37), in regulat-
ing protein phosphatase 2A activity.
DISCUSSION
In this study, we have demon-
strated that multiple and unex-
pected mechanisms of regulation of
SL levels exist in vivo. Thus,
although the mouse that we gener-
ated is defective only in synthesis of
ceramides containing very long acyl
chain fatty acids (i.e.C22–C24), lev-
els of ceramide and downstreamSLs
containing long acyl chains (i.e.
C16) were elevated, as were levels of
sphinganine.
The extent of the differences in
the SL profile between the WT and
CerS2 null mouse can be appreci-
ated by use of a pathway relational
map (9) that shows fold differences
in the amounts of SLs between each
mouse (Fig. 12) using a “heat map”
format. In this map, which depicts
each metabolite as a node con-
nected to its precursor and down-
stream metabolites, the hub of the
middle cluster shows the formation
of sphinganine from which radiates
each of the different chain length
N-acylsphinganines (dihydroceramides) produced by CerS,
which are next incorporated into dihydrosphingomyelins (left
branching nodes), dihydroceramide monohexoses (right
branching nodes), or desaturated to the respective ceramides
(Cer) (dashed lines to the right cluster) that are incorporated
into SM, HexCers (ceramide monohexoses), or turned over to
sphingosine (So) and sphingosine 1-phosphate (Fig. 12). This
depiction is particularly useful for drawing attention to the
metabolites that are elevated (Fig. 12, yellow to red) versus
reduced (blue), and the relationships are relatively easy to
appreciate. For example, by starting at the branch labeled 16 in
Fig. 12 and proceeding clockwise through the various chain
length subspecies, it is evident which subspecies are elevated
andwhich are lower in the CerS2 null mouse. It is also apparent
that sphinganine is much higher in the CerS2 null mouse and
that dihydro-SLs are elevated more than SLs.
Despite the dramatic changes in the SL profile, we have not
yet delineated the precise mechanisms leading to these
changes. Thus, although C16-ceramide levels are elevated,
there was no difference in C16-ceramide synthesis in vitro, and
none of the changes, or lack of changes in the activities of other
enzymes that metabolize ceramide, could explain these
changes, including N-SMase 2, which shows a preference for
degradation of very long acyl chain SM (38). One possibility is
that ceramides with different acyl chain lengths (i.e. long chain
versus very long chain) turn over with different rates and that
these rates are affected upon depletion of very long acyl chain
FIGURE 6. Activity of enzymes of ceramide metabolism. Activity was measured in liver homogenates (15–
200 g of protein) using fluorescent (NBD) lipid analogs. n 3–4; *, p 0.01.
FIGURE7.N-SMaseactivity.The left panel shows reverse transcription-PCRof
N-SMase 1 and 2 in WT versus CerS2 null mice at 1 month of age; hypoxan-
thine-guanine phosphoribosyltransferase 1 (HPRT) was used as a control for
RNA isolation and cDNA synthesis. The right panel shows N-SMase activity.
n 3; *, p 0.05.
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ceramides and SLs; unfortunately, nothing is known about the
rate of turnover of SLs with different acyl chains. Another pos-
sibility is that different hepatocytes express different comple-
ments of CerS genes (17) and that deletion of CerS2 in one type
of hepatocyte has unexpected consequences on the other type.
For instance, CerS2 is found at high levels in periportal hepato-
cytes but at lower levels in centrilobular hepatocytes (see Fig. 5
in Ref. 17). Assuming that CerS2 is themajor CerS in periportal
hepatocytes and that other CerS are found at low levels in these
cells, then sphinganine would accumulate in periportal hepato-
cytes of the CerS2 null mouse but would be consumed in cen-
trilobular hepatocytes, assuming that centrilobular hepatocytes
express a wider array of CerS genes. Interestingly, in a recent
study using small interfering RNA to CerS2 in cultured SMS-
KCNR neuroblastoma and MCF-7 breast cancer cells, no
changes in sphinganine levels were observed, although C16-
ceramide levels did increase in a similar manner to our study
(36).
Irrespective of the precisemolecular mechanism responsible
for sphinganine elevation, the increases in sphinganine levels
are reminiscent of those observed after treatment with fumoni-
sin (39) (a CerS inhibitor) (40) that results in elevation of sph-
inganine. Sphinganine levels have been determined after treat-
ment with fumonisin (10 mg/kg fumonisin, once per day for 5
days), with levels of 50 nmol/g of wet weight tissue (41).
Assuming that 3 g of wet tissue is equivalent to 1 g of dry
tissue (42), then sphinganine levels in the CerS2 null mouse
liver are 30 nmol/g of wet weight, a little lower than values
obtained after short term fumonisin treatment. In contrast,
sphinganine 1-phosphate is significantly elevated in liver after
fumonisin treatment (41) but barely changes in the CerS2 null
mouse.
While this study and the accompanying study (17) were in
preparation for publication, another study was published in
which the same mouse was generated (16). Although there are
some similarities between the two studies, our current study
contains significant additional information to that of Imgrund
et al. (16) as follows. (i) In the Imgrund et al. study (16), only one
time point was measured for SL analyses, namely 10 weeks. In
our study, we systematically analyzed SL levels for up to 4
months, including early time points in mouse development.
This is important because it permits prediction of the time in
which liver pathologymight be observed andwill help delineate
the primary events leading to pathology; interestingly, there is
little pathology until about 1month after birth (17) even though
SL levels (including sphinganine) are altered immediately after
birth. (ii) Imgrund et al. (16) did not measure long chain bases,
which could lead to the incorrect assumption that any pathol-
ogy observed would only be due to changes in the acyl chain
composition of SLs. In contrast, our data suggest that pathology
is likely due to a combination of changes in the acyl chain com-
position and also in sphinganine
levels; this is important because
considerable information is avail-
able about pathological changes
that occur in mouse liver upon
fumonisin consumption, which can
thus be compared and contrasted to
that obtained in the CerS2 null
mouse. (iii) Imgrund et al. (16) see
surprisingly high levels of C18-cer-
amide synthesis inWT liver relative
to the low amount of C18-ceramide,
-SM, and -HexCer that is found in
liver (15, 16); in addition, they see a
large reduction in C18-ceramide
FIGURE 8. Glycerophospholipid levels. Glycerophospholipid levels were
analyzed by nano-ESI-MS/MS in 30-day-old WT and CerS2 null mouse liv-
ers. A, glycerophospholipid levels are shown as a percent of total glycero-
phospholipids. n  4  S.D. B, distribution of fatty acid chains in phos-
phatidylethanolamine is shown. n  2. aPC, phosphatidylcholine (acyl
chains); ePC, phosphatidylcholine (ethyl chains); PE, phosphatidylethanol-
amine; PS, phosphatidylserine; PI, phosphatidylinositol; PG, phosphatidyl-
glycerol. n  3  S.D.; *, p  0.05.
FIGURE 9. Cholesterol levels. A, total cholesterol levels were measured by the ferric chloride method for 14-
and 30-day-oldmouse liver (n 3 S.D.). B, free (unesterified) cholesterol wasmeasured by nano-ESI-MS/MS
for 30-day-old liver (n 4).
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synthesis in the CerS2 null mouse. This is rather unexpected,
becauseCerS2 does not synthesize significant levels of C18-cer-
amide (15), suggesting that expression or activity of CerS1 (or
CerS4) (which both synthesize C18-ceramide (11)) has been
inexplicably altered under their experimental conditions. (iv)
Total ceramide, SM, andHexCer levels are reduced by 30–50%
in the liver of mice generated by Imgrund et al. (16), whereas
there are essentially no statistically significant changes in the
total levels of these lipids in our study. This difference may be
related to the one specific time point studied by Imgrund et al.
(16). However, it is of important functional consequence,
because we are able to exclude that any pathology we observe is
due to changes in total SL levels.
Although inactivation of theCerS2 gene has amajor effect on
the acyl chain composition of SLs and on levels of SL metabo-
lites, membrane fluidity is changed to a smaller extent than
might be predicted, suggesting that the membrane lipid com-
position of CerS2 null mice might be fine-tuned to maintain
overall fluidity. InWTmice, this property appears to be mainly
determined by the balance between very long chain saturated
SLs (which give a higher membrane order) and unsaturated
SLs (which give higher membrane fluidity) (Table 1 and
supplemental Tables 1 and 2). In the CerS2 null mouse, mem-
branes are depleted in unsaturated SLs, and thus membrane
order should increase. However, there is a concomitant enrich-
ment in saturated long chain (i.e. C16) SLs, which induce an
overall order lower than very long chain saturated SLs (44) lead-
ing to an overall decrease in order (fluidity increase). Despite
the similar degree of order in CerS2 null and WT membranes,
strong differences in membrane shape and curvature were
observed. Membrane morphology plays an important role in
cellular processes such as development and maintenance of
organelles, endocytosis, vesiculation, and lipid and protein
sorting (45). Indeed, it was recently shown that structural
motifs such as -helices and alkyl chains are able to sense dif-
ferences in membrane curvature and are susceptible to mem-
brane curvature-induced redistribution and sorting (46). In
addition, the endocytic sorting of lipids and proteins commonly
involves vesicular and tubular membranes, where the differ-
ences in lipid packing/membrane fluidity determine the route
FIGURE 10.Membrane biophysical properties andmorphology of micro-
somal lipids. A, fluorescence anisotropy of three different probes in micro-
somal lipid extracts obtained frommembranes of CerS2 null and WTmice at
30 days of age. n 3; *, p 0.001. B, confocal fluorescencemicroscopy show-
ing the morphological features of microsomal lipid extracts from WT (upper
panel) and CerS2 null mice (lower panel). Scale bar, 10 m.
FIGURE 11. Protein phosphatase 2A activity. Protein phosphatase 2A activ-
itywasmeasured in homogenates fromWTandCerS2 nullmouse liver. n 3.
FIGURE 12. Pathway relational map showing differences in the relative
amounts of sphingolipids in 60-day-old CerS2 null versus WT mouse
liver. The upper scheme (diagonal from lower left to upper right) summarizes
the biosynthetic pathway of SLs beginning with condensation of serine and
palmitoyl-CoA to 3-ketosphinganine (3-KetoSa) and then sphinganine (Sa),
which is either N-acylated (to N-AcylSa, dihydroceramide (DHCer)) or phos-
phorylated (Sa1P). N-Acylated sphinganine can be desaturated to N-acyl-
sphingosine (N-AcylSo, Cer), and both dihydroceramide and Cer can be con-
verted into SM or glycosylated to ceramidemonohexoses (CMH). Also shown
is the hydrolysis of Cer to sphingosine (upper right), which can undergo phos-
phorylation to sphingosine 1-phosphate. Other intermediates and products
of this scheme can also undergo turnover; some additional reactions (such as
ceramide phosphate formation) are not shown because their amounts are
small. The lower part of the figure depicts this pathway with all of the mea-
sured individualmolecular subspecies as nodes that havebeen colored in the
style of a heat map. The colors display the fold difference in the amounts of
each compounds inCerS2null versusWTmouse liver (i.e.CerS2/WT) using the
color scale shownat the lower right. Thus, the light blue circle at thebottom left
is for palmitoyl-CoA, followed by 3-ketosphinganine (3-keto-Sa) (which is
shown smaller and faded to reflect that the amounts in both samples were
too low for detection, but there was no evidence for accumulation of this
intermediate inCerS2nullmouse), thenby thenode for sphinganine,which is
deep redbecause sphinganinewas substantially higher in theCerS2nullmice.
Radiating from this hub are each N-acyl chain length metabolite of sphinga-
nine (for examples, N-palmitoylsphinganine is labeled 16, and N-nervonoyl-
sphinganine is labeled 24:1) (note that the former is elevated and the latter
reduced), followed by the respective dihydrosphingomyelins (DHSM) (left
nodes) and dihydroceramide monohexoses (DHCMH) (right nodes). Dashed
lines relate each N-acyl chain length dihydroceramide to the respective Cer,
which can be converted to SM and ceramide monohexose (outer nodes) or
hydrolyzed to sphinganine (at the hub of this diagram). The phosphorylation
products of sphinganine and So are also shown, labeled Sa1P and sphingo-
sine 1-phosphate (S1P). The data used for this figure are from Tables 1 to 3.
The layout of this scheme is from Ref. 9.
LipidMetabolism in a Ceramide Synthase 2 Null Mouse
APRIL 2, 2010•VOLUME 285•NUMBER 14 JOURNAL OF BIOLOGICAL CHEMISTRY 10909
 at N
ational Institutes of H
ealth Library on M
arch 28, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
of the sorting molecule (47, 48). Tubular structures were also
shown to play a major role in cell-to-cell communication and
intercellular transfer of organelles (43). Therefore, changing
the lipid profile in CerS2 null mice induces major alterations in
membrane morphology that may affect both intra- and inter-
cellular signaling. Furthermore, changes in themembrane lipid
composition and concomitant changes inmembranemorphol-
ogy in CerS2 null micemay disrupt several trafficking pathways
with various pathophysiological consequences.
In summary, the unexpected changes observed in the SL and
long chain base profile of the CerS2 null mouse liver, and in the
biophysical properties, implies much more complex pathways
of regulation of SL metabolism than previously envisaged.
Moreover, these changes cause a dramatic hepatopathy, as
reported in the accompanying study (17).
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